Intellia Therapeutics
Price & Volume
Stats
See more52W Range | $5.90-$21.46 |
Market Cap | $1.7B |
Shares Short | 34M |
Financials
See moreRevenue (12 Mos) | $52.8M |
Revenue Growth (YoY) | 104.8% |
Gross Profit (12 Mos) | -$387.2M |
Diluted EPS | -$4.69 |
News
See moreYahoo Finance • 2 days ago
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Yahoo Finance • 5 days ago
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Yahoo Finance • 9 days ago
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
Yahoo Finance • 22 days ago
Cathie Wood’s Ark Invest buys the dip in Figma as stock sinks ~20%
About
CEO | Dr. John M. Leonard M.D. |
Address | 40 Erie Street, Cambridge, MA, United States, 02139 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 403 |
